

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AIM Vaccine Co., Ltd.**

**艾美疫苗股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 06660)**

**(1) PROPOSED RE-ELECTION OF DIRECTORS IN THE SECOND SESSION;  
(2) PROPOSED RE-ELECTION OF SHAREHOLDER REPRESENTATIVE  
SUPERVISORS IN THE SECOND SESSION;  
(3) PROPOSED CHANGE OF REGISTERED OFFICE; AND  
(4) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

This announcement is made by the Company pursuant to Rule 13.51(1) and Rule 13.51(2) of the Listing Rules.

**PROPOSED RE-ELECTION OF DIRECTORS IN THE SECOND SESSION OF THE  
BOARD OF DIRECTORS**

As at the date of this announcement, the Board of Directors consists of eleven Directors, namely Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive Directors, Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive Directors, and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive Directors. Pursuant to the Articles of Association, a Director may be re-elected upon the expiry of his or her term.

The terms of all incumbent Directors expired on September 19, 2023. According to the Articles of Association, the incumbent Directors shall continue to perform the duties as director pursuant to the laws, administrative regulations, departmental rules and the Articles of Association until the elected director of the next session assumes his or her office. The Board of Directors proposed the nomination for the re-election of the Directors as follows:

- (i) Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as candidates for executive Directors;
- (ii) Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as candidates for non-executive Directors; and
- (iii) Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as candidates for independent non-executive Directors.

The above proposed re-election of the Directors will be submitted to the Shareholders for consideration and approval by way of ordinary resolutions at the EGM. If the above proposed re-election of the Directors is approved at the EGM, the terms of office of the candidates for Director will commence from the date on which the relevant resolutions are approved by the Shareholders at the EGM until the date of expiry of the term of the second session of the Board of Directors.

The biographical details of the above candidates for Director proposed for re-election are set out in Appendix I to this announcement.

Each of the candidates for independent non-executive Directors has confirmed that he or she meets the independence criteria as set out in Rule 3.13 of the Listing Rules and the Board of Directors considers that the above-mentioned candidates for independent non-executive Directors are independent pursuant to the independence criteria set out in Rule 3.13 of the Listing Rules.

As at the date of this announcement, (i) Mr. Yan ZHOU has an interest in 23,254,765 H Shares and 410,135,235 Domestic Shares within the meaning of Part XV of the SFO (same below); (ii) Mr. Shaojun JIA has an interest in 10,310,000 H Shares and 25,000,000 Domestic Shares; (iii) Mr. Jie ZHOU has an interest in 40,000,000 Domestic Shares; (iv) Mr. Xin ZHOU has an interest in 40,000,000 Domestic Shares; and (v) Ms. Aijun WANG has an interest in 25,000,000 H Shares and 25,000,000 Domestic Shares.

Save as disclosed in this announcement, as at the date of this announcement, each of the candidates for Director: (i) has not held any other positions in the Company or its subsidiaries; (ii) has not held any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas during the last three years; (iii) does not have any other major appointments and professional qualifications; (iv) does not have any relationship with any Directors, Supervisors, senior management or substantial or controlling Shareholders of the Company; and (v) does not have any interest in the shares of the Company which are within the meaning of Part XV of the SFO.

The Company will enter into a service contract with each of the above-mentioned candidates for Director in respect of their positions for a term of office of three years commencing from the date of approval by the Shareholders at the EGM until the date of the expiration of the term of office of the second session of the Board of Directors.

Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA will not receive any director's fee from the Company during their term but will receive remuneration based on their management positions with the Company. All non-executive Directors will not receive any director's salary or fee from the Company during their term. All independent non-executive Directors shall receive an annual allowance of RMB300,000 from the Company. The remuneration arrangement of the Directors is determined with reference to their experience, duties, responsibilities and the Company's remuneration policy. The Company will disclose the remuneration of Directors in its annual report each year.

Save as disclosed in this announcement, there is no information in relation to each of the above-mentioned candidates for Director that needs to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules. Save as mentioned in this announcement, there is no other matter in relation to the appointment of each of the candidates for Director that needs to be brought to the attention of the Shareholders.

## **PROPOSED RE-ELECTION OF SHAREHOLDER REPRESENTATIVE SUPERVISORS IN THE SECOND SESSION OF THE BOARD OF SUPERVISORS**

As at the date of this announcement, the Board of Supervisors consists of three Supervisors, namely Mr. Tingfeng SONG and Mr. Lun MA as Shareholder representative Supervisors and Mr. Jiashuai SONG as employee representative Supervisor. Pursuant to the Articles of Association, a Supervisor may be re-elected upon the expiry of his or her term.

The terms of all incumbent Supervisors expired on September 19, 2023. According to the Articles of Association, the incumbent Supervisors shall continue to perform the duties as supervisor pursuant to the laws, administrative regulations and the Articles of Association until the elected supervisor of the next session assumes his office.

The Board of Supervisors proposed the nomination for the re-election of Mr. Tingfeng SONG and Mr. Lun MA as candidates for Shareholder representative Supervisors.

The above proposed re-election of Shareholder representative Supervisors will be submitted to the Shareholders for consideration and approval by way of ordinary resolutions at the EGM. If the above proposed re-election of Shareholder representative Supervisors is approved at the EGM, the terms of office of the candidates for Shareholder representative Supervisor will commence from the date on which the relevant resolutions are approved by the Shareholders at the EGM until the date of expiry of the term of the second session of the Board of Supervisors.

The biographical details of the above candidates for Shareholder representative Supervisor proposed for re-election are set out in Appendix I to this announcement.

Save as disclosed in this announcement, as at the date of this announcement, each of the candidates for Shareholder representative Supervisor: (i) has not held any other positions in the Company or its subsidiaries; (ii) has not held any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas during the last three years; (iii) does not have any other major appointments and professional qualifications; (iv) does not have any relationship with any Directors, Supervisors, senior management or substantial or controlling Shareholders of the Company; and (v) does not have any interest in the shares of the Company which are within the meaning of Part XV of the SFO.

The Company will enter into a service contract with each of the above-mentioned candidates for Shareholder representative Supervisor in respect of their positions for a term of office of three years commencing from the date of approval by the Shareholders at the EGM until the date of the expiration of the term of office of the second session of the Board of Supervisors.

Mr. Tingfeng SONG shall receive an annual allowance of RMB300,000 from the Company. Mr. Lun MA will not receive any remuneration from the Company during his term as Supervisor. The remuneration of Supervisors is determined with reference to their relevant duties and responsibilities and the prevailing market rates.

Save as disclosed in this announcement, there is no information in relation to each of the above-mentioned candidates for Shareholder representative Supervisor that needs to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules. Save as mentioned in this announcement, there is no other matter in relation to the appointment of each of the candidates for Shareholder representative Supervisor that needs to be brought to the attention of the Shareholders.

In addition, an employee representative meeting of the Company will be held in due course to re-elect or elect the employee representative Supervisor, who will jointly form the second session of the Board of Supervisors with the Shareholder representative Supervisors to be re-elected at the EGM. The appointment of the employee representative Supervisor is not subject to the approval of the Shareholders. The employee representative Supervisor will not receive any supervisor's remuneration from the Company. The Company will update the Shareholders as and when appropriate.

## **PROPOSED CHANGE OF REGISTERED OFFICE**

The Board proposes to change the existing registered office of the Company in the PRC to the following:

Room 412, 4/F, Building 6, No. 105 Jinghai 3rd Road, Beijing Economic-Technological Development Area, Beijing  
北京市北京經濟技術開發區經海三路105號院6號樓4層412室

The above proposed change of registered office of the Company (the “**Proposed Change of Registered Office**”) is subject to the completion of the relevant registration procedures with the State Administration for Market Regulation (國家市場監督管理總局).

A special resolution will be proposed at the EGM, the Domestic Share Class Meeting and the H Share Class Meeting to consider and approve the Proposed Change of Registered Office and the relevant proposed amendments to the Articles of Association.

## **PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

The Board of Directors proposes to amend the existing Articles of Association by adopting a new set of Articles of Association in substitution for, and to the exclusion of, the existing Articles of Association (the “**Proposed Amendments**”), in view of the below and to make some other housekeeping amendments.

On February 17, 2023, the State Council (the “**State Council**”) of the PRC issued the Decision of the State Council to Repeal Certain Administrative Regulations and Documents (《國務院關於廢止部分行政法規和文件的決定》) and the China Securities Regulatory Commission (the “**CSRC**”) issued the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (《境內企業境外發行證券和上市管理試行辦法》) (the “**Trial Measures**”) and related guidelines, which came into effect on March 31, 2023. Meanwhile, the Mandatory Provisions for Companies Listing Overseas (《到境外上市公司章程必備條款》) (the “**Mandatory Provisions**”) set forth in Zheng Wei Fa (1994) No. 21 file issued on August 27, 1994 by the State Council Securities Policy Committee and the State Commission for Restructuring the Economic System and the Special Regulations on the Overseas Offering and Listing of Shares by Joint Stock Limited Companies (《國務院關於股份有限公司境外募集股份及上市的特別規定》) issued on August 4, 1994 by the State Council had been repealed on the effective date of the Trial Measures. PRC issuers shall formulate their articles of association with reference to the Guidelines on Articles of Association of Listed Companies (《上市公司章程指引》) issued by the CSRC in place of the Mandatory Provisions. Furthermore, holders of domestic shares and H shares are no longer deemed to be different classes of shareholders, thus the class meeting requirement applicable to holders of domestic shares and H shares are no longer necessary and removed. In light of the above, the Stock Exchange also proposed certain amendments to the Listing Rules, which came into effect on August 1, 2023.

The Board of Directors is of the view that the Proposed Amendments (including the removal of the class meeting requirement from the Articles of Association following the repeal of the Mandatory Provisions) will not compromise protection of the H Shareholders and will not have material impact on measures relating to shareholder protection, as domestic shares and H shares are regarded as one class of ordinary shares under PRC law, and the substantive rights attached to these two kinds of shares (including voting rights, dividends and asset distribution upon liquidation) are the same.

After the Proposed Amendments take effect, the Company will continue to comply with the Listing Rules to meet the core shareholder protection standards through compliance with PRC laws in combination with its constitutional documents pursuant to Appendix 3 of the Listing Rules and will further monitor its ongoing compliance with these standards and notify the Stock Exchange if it becomes unable to comply with any of these standards.

The proposed amendments to the Articles of Association shall be subject to the passing of a special resolution by the Shareholders of the Company at the EGM, the Domestic Share Class Meeting and the H Share Class Meeting, and will become effective upon the approval by the Shareholders at the EGM, the Domestic Share Class Meeting and the H Share Class Meeting.

## **DESPATCH OF CIRCULAR**

A circular containing, among other matters, details of (1) the proposed re-election of Directors; (2) the proposed re-election of the Shareholder representative Supervisors; (3) the proposed change of registered office; and (4) the proposed amendments to the Articles of Association and the notices of the EGM and the H Share Class Meeting will be despatched to the Shareholders in due course.

## **DEFINITIONS**

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings:

“Articles of Association”	the articles of association of the Company
“Board of Directors”	the board of directors of the Company
“Board of Supervisors”	the board of supervisors of the Company
“Company”	AIM Vaccine Co., Ltd. (艾美疫苗股份有限公司), a joint stock company incorporated in the PRC with limited liability on November 9, 2011, the H Shares of which are listed on the Main Board of the Stock Exchange (stock code: 06660)
“controlling shareholder(s)”	has the meaning ascribed to it under the Listing Rules
“Director(s)”	the director(s) of the Company
“Domestic Share(s)”	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which is (are) subscribed for and paid up in Renminbi by PRC domestic investors and not listed on any stock exchange

“Domestic Share Class Meeting”	the 2023 third class meeting for holders of Domestic Shares of the Company to be held immediately after the conclusion of or any adjourned meeting of the EGM on November 28, 2023
“EGM”	the 2023 second extraordinary general meeting of the Company to be held on or around November 28, 2023
“H Share(s)”	overseas listed foreign share(s) in the issued share capital of the Company, with a nominal value of RMB1.00 each, listed on the Stock Exchange
“H Share Class Meeting”	2023 third H share class meeting
“H Shareholder(s)”	holder(s) of H Shares
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange, as amended and supplemented from time to time
“PRC”	the People’s Republic of China
“RMB”	Renminbi, the lawful currency of the PRC
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, modified or otherwise supplemented from time to time
“Share(s)”	share(s) in the share capital of the Company with a nominal value of RMB1.00 each, comprising Domestic Share(s) and H Share(s) as at the date of this announcement
“Shareholder(s)”	holder(s) of the Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“substantial shareholder(s)”	has the meaning ascribed to it under the Listing Rules
“Supervisor(s)”	supervisor(s) of the Company
“%”	per cent

By order of the Board  
**AIM Vaccine Co., Ltd.**  
**Mr. Yan ZHOU**

*Chairman of the Board, Executive Director and Chief Executive Officer*

Hong Kong, November 9, 2023

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.*

## APPENDIX I – BIOGRAPHICAL DETAILS OF THE DIRECTORS AND SHAREHOLDER REPRESENTATIVE SUPERVISORS FOR RE-ELECTION

### Biographical details of the Directors for Re-election

#### *Executive Directors*

**Mr. Yan ZHOU (周延)**, aged 58, is an executive Director, chairman of the Board and the chief executive officer of our Company. He has served as a Director of our Company since May 2015 and was re-designated as an executive Director on June 9, 2021. Mr. Zhou has served as the chairman of the board of AIM Explorer Biomedical R&D Co., Ltd. (艾美探索者生命科學研發有限公司) (“**AIM Explorer**”) since February 2021, the executive director of AIM Explorer since May 2021 and the chairman of the board of Liverna Therapeutics Inc. (珠海麗凡達生物技術有限公司) since May 2021.

Mr. Zhou has around 10 years of experience in the biopharmaceutical industry, including experience in investment and management. Since May 2012, he has been the chairman of the board of Tibet Tianxia Holdings Group Co., Ltd. (西藏天下控股集團股份有限公司), a company engaged in venture capital investment and management with an aggregate investment of over RMB630 million between 2012 and 2021 in a number of pharmaceutical, consulting, management, investment, financial information and financing companies, where Mr. Zhou is primarily responsible for the overall work of the company. Mr. Zhou was a director of Liaoning Green Biological Pharmaceutical Group Co., Ltd. (遼寧格林生物藥業集團股份有限公司) (“**Liaoning Green Biological**”), a company engaged in the development and production of drugs such as small volume injections, freeze-dried powder injections, active pharmaceutical ingredients, tablets, hard capsules and drug mixtures with a registered capital of RMB115 million and net assets of approximately RMB130 million, from May 2013 to August 2018 and the chairman of its board from October 2011 to May 2013.

Mr. Zhou has invested in a number of pharmaceutical and healthcare companies. He indirectly owns Green Biological Group Co., Ltd. (格林生物集團有限公司) (“**Green Biological**”), a company engaged in the development of rehabilitation and gene immunotherapy technologies with a registered capital of RMB999.99 million, as to approximately 66.44%, which in turns directly owns (i) Liaoning Green Biological as to 73.02%, (ii) Green Immunoscience Co., Ltd. (格林免疫科學有限公司), a holding company which is a sole shareholder of Green Biopharmaceutical Technology (Tianjin) Co., Ltd. (格林生物醫藥科技(天津)有限公司), as to 76%, (iii) Aier Health Medicine (Liaoning) Co. Ltd. (艾爾健康醫藥(遼寧)有限公司), an innovative ophthalmological medicine research and development and manufacturing company, as to 75%, (iv) Aier Aesthetic Medicine (Shenyang) Co., Ltd. (瀋陽艾爾醫療美容有限公司), a company engaged in the research and development of aesthetic medicine, as to 70%, and (v) Liaoyang Jiade Blood Products Co., Ltd. (遼陽嘉德血液製品有限公司), a company engaged in the production of blood products, as to 51%, and indirectly owns Green Biopharmaceutical Technology (Tianjin) Co., Ltd. (格林生物醫藥科技(天津)有限公司), a company engaged in the research and development of the diagnosis of allergic diseases and respiratory infectious diseases and related immunotherapies for allergic diseases, as to 76%. Additionally, Mr. Zhou directly owns Huamei Genome Editing (Liaoning) Co., Ltd. (華美基因編輯技術(遼寧)有限公司), a company which has not yet commenced business operation, as to 99.99%.

Mr. Zhou obtained his master of business administration from Tsinghua University (清華大學) in the PRC in December 2014, and his doctor's degree of business administration from the W. P. Carey School of Business of Arizona State University in the U.S. (“**W. P. Carey**”) in May 2015, and his master of business administration from Peking University (北京大學) in the PRC in January 2022. Mr. Zhou is also an honorary member of Westlake University Board of Trustees (西湖大學榮譽董事). He is the brother of Mr. Jie ZHOU and Mr. Xin ZHOU, the non-executive directors of the Company.

**Mr. Wen GUAN (關文)**, aged 57, is an executive Director and an executive president of our Company and is responsible for assisting the chief executive officer to preside over the internal management of the Company. He has served as a Director of our Company since February 2021 and was re-designated as an executive Director on June 9, 2021. Prior to that, Mr. Guan served as a Director of our Company since December 2016 and served as the chairman of the supervisory committee of the Company from June 2020 to February 2021. He has been the chairman of the board of AIM Action BioPharm Co., Ltd. (艾美行動生物製藥有限公司) since March 2021.

From November 2015 to August 2016, Mr. Guan was a director of TD Capital (Hong Kong) Management Company Limited, a company primarily engaged in equity investment, where Mr. Guan was primarily responsible for investment management. From October 2014 to November 2015, Mr. Guan served as the director of TD Capital Management Company Limited, a company primarily engaged in project investment, where Mr. Guan was primarily responsible for investment management.

Mr. Guan received his executive master of business administration degree from Shanghai Jiao Tong University (上海交通大學) in the PRC in March 2014 and his master's degree in business administration from Cheung Kong Graduate School of Business (長江商學院) in the PRC (“**CKGSB**”) in September 2008.

**Mr. Shaojun JIA (賈紹君)**, aged 61, has served as a Director of our Company since August 2017 and was re-designated as an executive Director on June 9, 2021. Mr. Jia also has served as an executive president of our Company since February 18, 2021, and has served as the chief operating officer of our Company since March 29, 2023. Mr. Jia is a director of AIM Explorer since December 2020, the chairman of AIM Weixin Biopharmaceutical (Zhejiang) Co., Ltd. (艾美衛信生物藥業(浙江)) since March 2021, and the chairman of the board of Ningbo Rong'an Biological Pharmaceutical Co., Ltd. (寧波榮安生物藥業有限公司) since June 2021.

Mr. Jia has been a senior partner, member of the decision-making committee, executive president and general manager of Tibet Tongxin Capital Investment Management Co., Ltd. (西藏同信資本投資管理有限公司) from April 2017 to February 2021, a company primarily engaged in investment and asset management. From January 2007 to March 2017, he served as the chairman and general manager of Tibet Tongxin Securities Co., Ltd. (西藏同信證券股份有限公司), a company primarily engaged in securities trading and financial consulting. From August 1998 to September 2007, he held various positions at Guotai Junan Securities Co., Ltd. (國泰君安證券股份有限公司) (SSE: 601211; SEHK: 2611), such as executive vice president, assistant to chief executive officer and director of the marketing and sales of department. From September 1992 to August 1999, Mr. Jia was a branch general manager of Guotai Securities Co., Ltd. (國泰證券有限公司).



Mr. Jia received his bachelor's degree in business enterprise management from Henan Radio & Television University (河南廣播電視大學) (currently known as the Open University of Henan (河南開放大學)) in the PRC in July 1986 and obtained his executive master of business administration degree from W. P. Carey in May 2006.

### ***Non-executive Directors***

**Mr. Jie ZHOU (周杰)**, aged 60, has served as a Director of our Company since May 2015 and was re-designated as a non-executive Director on June 9, 2021. Mr. Jie ZHOU served as the manager of our Company from December 2015 to December 2016 and the chairman of the Board from December 2016 to September 2020.

Mr. Jie ZHOU has served as a director of Tibet Tianxia Holdings Group Co., Ltd. (西藏天下控股集團股份有限公司) since May 2012. From May 2013 to May 2017, he has held various management positions at Liaoning Green Biological Pharmaceutical Group Co., Ltd. (遼寧格林生物藥業集團股份有限公司), including chairman, director and manager. In terms of his investment experiences, Mr. Jie ZHOU directly owns Jiuding Cellular Therapy Industry (Liaoning) Co., Ltd. (九鼎細胞治療產業(遼寧)有限公司), a company which has not commenced business operation, as to 99.99%, which in turn invests in Green Biological.

Mr. Jie ZHOU received his master's degree in business administration from CKGSB in September 2013. He is the brother of Mr. Yan ZHOU, the Executive Director, Chairman of the Board and CEO and the controlling shareholder of the Company, and Mr. Xin ZHOU, the non-executive director of the Company.

**Mr. Xin ZHOU (周欣)**, aged 55, has served as a Director of our Company since May 2013 and was re-designated as a non-executive Director on June 9, 2021.

Prior to joining our Company, Mr. Xin ZHOU was an executive director and manager at Tibet Silicon Valley Angel Venture Capital Co., Ltd. (西藏硅谷天使創業投資有限公司) from June 2010 to December 2020. In terms of his investment experiences, Mr. Xin ZHOU directly owns Woye Biotechnology (Liaoning) Co., Ltd. (沃野生物技術(遼寧)有限公司), a company which has not commenced business operation, as to 99.99%, which in turn invests in Green Biological.

Mr. Xin ZHOU studied for an executive master of business administration from CKGSB in 2012 and received an executive master of business administration from Tsinghua University (清華大學) in June 2022. He is the brother of Mr. Yan ZHOU, Executive Director, Chairman of the Board and CEO and the controlling shareholder of the Company, and Mr. Jie ZHOU, non-executive director of the Company.

**Mr. Jichen ZHAO (趙繼臣)**, aged 60, has served as a Director of our Company since June 2020 and was re-designated as a non-executive Director on June 9, 2021.

Mr. Zhao has been the chairman of Shanghai China UniCredit Investment Development Co., Ltd. (上海中聯信投資發展股份有限公司) since February 2023. He has been the chairman of China UniCredit International Group Company Limited (中聯信國際集團有限公司) since February 2017, a company primarily engaged in international trade, where he is primarily responsible for the overall leadership of the company's operations, development and daily business affairs. From January 2013 to January 2017, Mr. Zhao served as an executive director and vice president at the head office of Ping An Bank (平安銀行), where he was primarily responsible for risk management. From March 2002 to January 2013, Mr. Zhao held various senior management positions at China Minsheng Bank (中國民生銀行), including general manager of the risk management department, executive vice president, and risk management director. He also worked as a manager at the Industrial and Commercial Bank of China (中國工商銀行) from February 1984 to January 2002 and as a manager of the second-level branch of the People's Bank of China (中國人民銀行) from September 1982 to January 1984.

Mr. Zhao received his master's degree in business administration from Dalian University of Technology (大連理工大學) in the PRC in July 2006, and his doctor of business administration (global financial management) from W.P. Carey in 2015. He is a qualified senior economist recognized by the Industrial & Commercial Bank of China Senior Economist Appraisal Committee (中國工商銀行高級經濟師評審委員會) since August 1997.

**Ms. Aijun WANG (王愛軍)**, aged 51, has served a Director of our Company since September 2017 and was re-designated as a non-executive Director on June 9, 2021.

Since February 2017, Ms. Wang has been the group chairwoman of the board of directors of MeiHua Holdings Group Co., Ltd. (梅花生物科技集團股份有限公司) (SSE: 600873) and served as its group general manager from April 2009 to February 2017. From March 2008 to April 2009, Ms. Wang served as the group general manager at Hebei MeiHua MSG Co., Ltd. (河北梅花味精有限公司). From January 1998 to March 2008, Ms. Wang worked as a sales manager assistant at Langfang MeiHua MSG Co., Ltd. (廊坊梅花味精有限公司).

As of December 31, 2022, Ms. Wang served as the sole director of Lhasa Meihua Biological Investment Holdings Co., Ltd. (拉薩梅花生物投資控股有限公司), which has a discloseable interest in the Shares pursuant to Part XV of the SFO.

Ms. Wang completed the executive master of business administration course in CKGSB in October 2009. She received her bachelor's degree in business management from Harbin Institute of Technology (哈爾濱工業大學) in the PRC in January 2017 and completed her financial chief executive officer course in CKGSB in October 2016. She has been studying for a program in global technology and finance development at the PBC School of Finance of Tsinghua University (清華大學五道口金融學院) in the PRC since October 2016.

## ***Independent non-executive Directors***

**Professor Ker Wei PEI**, aged 66, was appointed as our independent non-executive Director on September 19, 2020.

Professor Pei was a tenured professor of accountancy at W. P. Carey from July 1998 to May 2022. He was the assistant lecturer of W. P. Carey from January 1986 to June 1992, associate professor from July 1992 to July 1998, high-tech master of business administration from July 1998 to June 2003, associate dean from July 2003 to June 2013, and dean of the China Program from July 2013 to June 2017. Professor Pei was the chairman of the American Accounting Association's Globalization Initiatives Committee from 1997, and the president of the Chinese Accounting Professors' Association of North America (北美華人會計教授協會) from 1993 to 1994.

Professor Pei has served as an independent non-executive director of Zhejiang Expressway Co., Ltd. (SEHK: 0576) (“**Zhejiang Expressway**”) since June 2012, an independent non-executive director of Want Want China Holdings Limited (SEHK: 0151) since June 2007, and an independent non-executive director of Zhong An Group Limited (formerly known as Zhong An Real Estate Limited) (SEHK: 0672) since June 2008. Professor Pei served as an independent non-executive director of MMG Limited (SEHK: 1208) from July 2015 to December 2019 and Baoshan Iron & Steel Co., Ltd. (SSE: 600019) from May 2006 to May 2012, and as an external director of China Merchants Group Limited (招商局集團有限公司) from June 2015 to May 2022, and of China Baowu Steel Group Corporation Limited (中國寶武鋼鐵集團), the holding company of Baoshan Iron & Steel Co., Ltd., from February 2012 to September 2019. In particular, Professor Pei has served as the chairman of the audit committee of Zhejiang Expressway since April 2018, where he reviewed financial statements for the quarterly, interim and annual results, discussed the internal audit, the effectiveness of internal control system and total risk management, and made recommendation on the re-appointment of external auditors.

Professor Pei received his bachelor's degree in accounting in June 1979, his master's degree in accountancy from Southern Illinois University in the U.S. in May 1981, and his PhD degree from the University of North Texas in the U.S. in May 1986. He is a member of American Accounting Association.

**Mr. Xiaoguang GUO (郭曉光)**, aged 51, was appointed as our independent non-executive Director on February 18, 2021.

From September 2017 to February 2021, Mr. Guo was the general manager of Huaxi Jinzhi Investment Co., Ltd. (華西金智投資有限責任公司), a company primarily engaged in investment. From March 2011 to October 2017, he served as an assistant to the president and a general manager of the investment banking head office of Huaxi Securities Co., Ltd. (華西證券股份有限公司). From February 1998 to February 2011, he served as a senior manager, deputy general manager and general manager successively of the business department of the investment banking division of Guosen Securities Company Limited (國信證券股份有限公司).

Mr. Guo received his bachelor's degree in economics from Beijing Business College (北京商學院) (currently known as the Beijing Technology and Business University (北京工商大學)) in the PRC in June 1993 and his master's degree in business administration from CKGSB in October 2009. He obtained the qualification certificate of independent directors from the Shanghai Stock Exchange in April 2021.

**Mr. Hui OUYANG (歐陽輝)**, aged 60, was appointed as our independent non-executive Director on May 28, 2021.

Mr. Ouyang is the dean's distinguished chair professor of finance of CKGSB and is the academic director of the executive master of business administration program since July 2019. He was also an associate professor of finance in CKGSB from December 2010 to February 2013 and its associate dean of the master of business administration program from January 2018 to June 2019. Before joining CKGSB, Mr. Ouyang worked at a number of investment banks including UBS AG, Nomura Securities Co., Ltd. and Lehman Brothers Holdings Inc.

Mr. Ouyang was the independent non-executive director of Duiba Group Limited (HKEX: 1753) from April 2019 to June 2022 and of Ping An Insurance (Group) Company of China, Ltd. (HKEX: 2318) from August 2017 to July 2023.

Mr. Ouyang received his bachelor's degree in chemistry from Hunan Normal University (湖南師範大學) in the PRC in July 1982 and his master's degree in chemistry from Peking University (北京大學) in the PRC in July 1985. Mr. Ouyang also received his PhD degree from Tulane University in the U.S. in December 1990, his post-doctorate degree in chemical physics from California Institute of Technology in the U.S. in October 1993 and his PhD degree in business administration from the University of California, Berkeley in the U.S. in May 1998.

**Ms. Jie WEN (文潔)**, aged 59, was appointed as our independent non-executive Director on May 28, 2021.

Ms. Wen has been the chairwoman of Beijing Allwegene Technology Co., Ltd. (北京奧維森基因科技有限公司) since March 2014. From March 2011 to March 2014, she worked as the strategy and planning officer of the Sinopharm CNBG (China National Pharmaceutical Group, China National Biotech Group) (中國國藥集團中國生物技術股份有限公司). From August 2001 to February 2011, she served as the vice president of Shenzhen BGI Technology Co., Ltd. (深圳華大基因科技有限公司) (SZSE: 300676), a company primarily engaged in genomics research and development. From March 1985 to July 2001, she worked as the officer of diagnostic supplies at Lanzhou Institute of Biological Products Co., Ltd. (蘭州生物製品研究所有限責任公司). In 2004, she was engaged as an adjunct professor by HeXi University (河西學院).

Ms. Wen received her college degree in chemistry from HeXi University in the PRC in 1981 and her doctorate degree of health administration from Warnborough College in Ireland on December 31, 2021. Ms. Wen is recognized by the Ministry of Health of the PRC as a senior engineer in medical biologics engineering in 1997.

In November 2015, Ms. Wen was granted the National Science and Technology Progress Award (國家科學技術進步獎) by the State Council of China for her series of studies on Etiology and prevention of SARS.

## **Biographical details of the Shareholder Representative Supervisors for Re-election**

**Mr. Tingfeng SONG (宋廷鋒)**, aged 55, has served as the chairman of the Board of Supervisors since February 2021.

From May 2012 to December 2019, Mr. Song served as a senior vice president, chief financial officer and secretary to the board of directors of Trendy (China) Group Co., Ltd. (赫基(中國)集團股份有限公司), a company primarily engaged in clothing wholesale and retail, and goods wholesale. He was the chief financial officer of China National Pharmaceutical Group Co., Ltd. (中國生物技術集團公司) from June 2010 to December 2011, CNBG from December 2006 to June 2010, and China National Medicines Corporation Ltd. (國藥集團藥業股份有限公司) (SSE: 600511) from July 2003 to December 2006. From June 2010 to December 2011, Mr. Song has served as an independent non-executive director of Bringspring Science and Technology Co., Ltd. (榮科科技股份有限公司) (SZSE: 300290), a company primarily engaged in the technologies relating to smart medicine and smart cities. He has also served as an independent non-executive director of SIASUN Robot & Automation Co., Ltd. (瀋陽新松機器人自動化股份有限公司) (SZSE: 300024) since May 2014, a company primarily engaged in robotics and automation equipment.

Mr. Song received his master's degree in accounting from Liaoning University (遼寧大學) in the PRC in June 1999. He was awarded his PhD degree in management and his PhD degree in accounting from Renmin University of China (中國人民大學) in June 2002 and July 2002 respectively. He received the title of senior accountant in 2005.

**Mr. Lun MA (馬倫)**, aged 61, has served as a Supervisor of our Company since December 2015.

Mr. Ma has over 25 years of experience in financial accounting, treasury, corporate finance and taxation matters. He has served as the finance director of Tibet Silicon Valley Angel Venture Capital Co., Ltd. (西藏硅谷天使創業投資有限公司), a company primarily engaged in project investment, investment management and investment consulting, since September 2008 and was the finance manager of Shen Yang Fang Tian Co., Ltd. (瀋陽房天股份有限公司), a company primarily engaged in real estate, from August 1992 to August 2008.

Mr. Ma graduated from the department of economics of Shenyang Radio and Television University (瀋陽市廣播電視大學) with a major in industrial statistics in the PRC in July 1986, and has been an accountant since June 1992.